Coagulation factor VIIa

Coagulation factor VIIa (also known as Activated Factor VII or FVIIa) is a man-made form of a protein found in the body. It's used to treat certain types of bleeding in people with hemophilia A or B who have developed inhibitors. It works by stimulating the body's natural clotting process to help stop or reduce bleeding. Coagulation factor VIIa is given as an injection directly into a vein (IV) or muscle (IM).

Coagulation Factor VIIa (rFVIIa)

Coagulation factor VIIa (rFVIIa), also known as recombinant activated factor VII, is a lab-made form of activated factor VII, a protein naturally produced in the liver that plays a crucial role in the blood clotting process.

Here's a deeper look at rFVIIa:

Function:

  • Similar to natural factor VIIa: Like its naturally occurring counterpart, rFVIIa triggers and amplifies the clotting cascade, ultimately leading to the formation of a blood clot.
  • More potent than natural factor VII: Unlike natural factor VII, rFVIIa is already in its activated form, making it more potent and faster-acting in initiating the clotting process.

Medical uses:

  • Treating and preventing bleeding in individuals with deficiencies: This includes:
    • Congenital factor VII deficiency: A rare genetic disorder where the body doesn't produce enough factor VII.
    • Acquired factor VII deficiency: This can occur due to liver disease, vitamin K deficiency, or certain medications.
  • Treatment of bleeding episodes in specific situations:
    • Hemophilia A or B with inhibitors: When individuals with these bleeding disorders develop antibodies that block the effectiveness of other clotting factor replacement therapies (e.g., factor VIII or IX).
    • Severe uncontrolled bleeding during surgery or trauma: In some cases, rFVIIa can be used as an additional treatment to promote clot formation.

Important considerations:

  • Not a first-line treatment: rFVIIa is typically not the first-line treatment for most bleeding disorders due to:
    • High cost: rFVIIa is an expensive medication.
    • Potential for side effects: rFVIIa can cause serious side effects, including:
      • Blood clots: This is a major concern, as rFVIIa promotes clot formation, and inappropriate clotting can lead to serious complications like stroke, heart attack, or pulmonary embolism (blood clot in the lung).
      • Allergic reactions: While rare, allergic reactions can occur.
  • Off-label use: While rFVIIa is approved for specific indications, it may be used off-label by healthcare professionals in certain situations based on their clinical judgment.

It is crucial to consult with a healthcare professional for proper diagnosis and treatment if you have concerns about bleeding disorders or suspect a factor VII deficiency. They can assess your individual needs and determine the most appropriate course of treatment, considering the potential benefits and risks of rFVIIa and other options.


 

Anatomical Therapeutic Chemical Classification
B - Blood and blood forming organs
B02 Antihemorrhagics
B02B - Vitamin K and other hemostatics
B02BD Blood coagulation factors
External Links